Every 10-Q that Abeona Therapeutics Inc. (ABEO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ABEO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABEO filings page.
Abeona Therapeutics Inc. reported its first full quarters of product revenue from ZEVASKYN for the period ended June 30, 2026. Product revenue, net, reached $11.4 million for the quarter and $20.1 million for the first six months of 2026, compared with none in the prior-year periods. Total revenues were the same amounts, as there were no 2026 license revenues.
The company recorded a quarterly net loss of $20.2 million and a six‑month net loss of $37.3 million, versus net income of $108.8 million and $96.8 million in the comparable 2025 periods, which had included a $152.4 million gain from the sale of a priority review voucher. Loss from operations narrowed year over year.
Cash and cash equivalents were $56.2 million and short‑term investments were $90.6 million as of June 30, 2026, with net cash used in operating activities of $37.3 million for the first half. Total debt under the term loan was $15.0 million and warrant liabilities were carried at fair value of $20.7 million. Management states that existing capital resources are expected to fund operations for at least 12 months from issuance of these statements.
Abeona Therapeutics reported its first meaningful commercial quarter for ZEVASKYN, generating $8.7 million in product revenue for the three months ended March 31, 2026. This compares to no revenue in the same period of 2025.
The company posted a net loss of $17.1 million, versus a $12.0 million loss a year earlier, as selling, general and administrative expenses rose to $19.5 million and research and development held roughly flat at $9.6 million. Loss from operations was $23.0 million.
Cash and cash equivalents were $61.4 million and short-term investments were $106.9 million, supporting total assets of $198.5 million and stockholders’ equity of $144.9 million. Management concluded existing capital resources are sufficient to fund operations for at least 12 months.
During the quarter Abeona signed a new license and joint development agreement with Reverence Enterprises for PSMA SIR-T T-cell therapy for prostate cancer, paying a $7.0 million upfront fee that was expensed as research and development. Warrant liabilities declined to $13.5 million as their fair value decreased.
Abeona Therapeutics (ABEO) reported Q3 2025 results, reflecting the first months after FDA approval of ZEVASKYN for RDEB. The quarter showed a net loss of $5.2 million, compared with a $30.3 million loss a year ago, as commercialization spending ramped. Year-to-date, the company recorded $91.6 million in net income, largely from a $152.4 million gain on the sale of a Priority Review Voucher.
Liquidity strengthened: cash and cash equivalents were $82.9 million and short‑term investments were $124.2 million as of September 30, 2025. Stockholders’ equity rose to $171.2 million. Q3 operating expenses included R&D $4.2 million and SG&A $19.3 million as the company built out commercial infrastructure and manufacturing capacity. Inventory totaled $4.9 million (raw materials). Warrant liabilities declined to $22.6 million. The company maintained a $20.0 million senior term loan; an amendment on July 18, 2025 reduced the interest rate to a fixed 11.75% and included issuance of 16,473 new warrants. Common shares outstanding were 54,191,361 as of November 7, 2025.
Abeona Therapeutics reported a materially different quarter driven by regulatory and one-time transaction events. The FDA approved ZEVASKYN on April 28, 2025, and the company recognized a $152.4 million gain from the sale of a Priority Review Voucher, producing net income of $108.8 million for the three months ended June 30, 2025 and $96.8 million for the six months ended June 30, 2025. Cash and cash equivalents rose to $163.5 million and short-term investments were $62.0 million, increasing total assets to $246.2 million and stockholders' equity to $163.6 million as of June 30, 2025.
Operationally the company remains a commercial-stage biopharmaceutical developer of cell and gene therapies: license revenues were modest ($0.4 million) and the six-month loss from operations before the PRV gain was $42.5 million. Debt principal under the Loan Agreement remains $20.0 million with current maturities of $5.6 million and a covenant to maintain $5.0 million in unrestricted cash. Warrant liabilities totaled $30.2 million. Management states available capital resources are sufficient to fund operations for at least the next 12 months.